What does the Landscape Review cover?
- The Drug Landscape – Explore all of the new, approved, and discontinued bispecific assets from H1 2024.
- The Trial Landscape & Regulatory Announcements – Dive into the surge in number of bispecific trials over the last 4 years, identify top disease indications, and view a list of completed trials and the latest regulatory updates.
- The Commercial Landscape & Future of Bispecifics – Unlock exclusive insights into the top deals and leading companies of H1 2024, along with a preview of key assets to look out for in the second half of the year.
You may also be interested in...
H1 2024 Immune Tolerance Landscape Review
H1 2024 Bispecific Landscape Review
H1 2024 Checkpoint Landscape Review
H1 2024 ADC Landscape Review
Unlocking the Potential of Bispecific ADCs
Investment Trends in Early-Stage Biopharma: A Beacon Data Perspective
Find out more
Beacon is the essential decision-support tool for developers of complex therapeutics. Our market-defining, proprietary ontologies combined with the most accurate and comprehensive life sciences data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
Each dataset features proprietary, hyper-relevant search and filtering tailored to specific modalities, in-depth data, plus additional market insight curated by our subject matter experts. Beacon is here to support you in making these decisions with confidence through our encompassing database solution.
With Beacon, you can make drug development decisions with confidence. This is why 23 out of the world’s top 25 drug developers trust us.
Any questions? Get in touch
Our dedicated account and research teams can help you with questions by showing you how this insight and data is collated on Beacon.
